Inovio promotes Niranjan Sardesai to COO
This article was originally published in Scrip
Executive Summary
Inovio Pharmaceuticals, which is developing vaccines to fight cancers and infectious diseases, has promoted Dr Niranjan Sardesai from senior vice-president of research and development to chief operating officer. In addition, Kevin Rassas, Inovio's senior vice-president of business development, has retired. Dr Sardesai will incorporate corporate and business development responsibilities into his expanded role. Dr Sardesai joined VGX Pharmaceuticals in 2006, before the company merged with Inovio in June 2009.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.